Searched for
API MANUFACTURERS
Global creditors drag Udaan's parent to bankruptcy court in Singapore after $170-million bond defaultInsolvency petition filed this week, A&M appointed as liquidator of B2B commerce company. Ten year old co has seen valuations crash 70% as ...- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsIn just a few days, the Q1 earnings season for FY27 will start. But before that will come the season of business updates. And that needs to...
- For low risk-takers: 5 large-caps from different sectors with an upside potential of up to 31%Now, there is nothing wrong with being bullish, because it has always paid to be bullish. Yes, one might argue that it has not paid in the ...
- Beyond refunds: Why GST 2.0 is a growth enabler for MSME exportersLiquidity alone won’t close the credit gap that most Indian MSME exporters face. This is where GST 2.0 has its most underappreciated impact...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...
- Trade disruptions, API dependence, compliance costs: Pharma MSMEs spell out policy priorities on World MSME DayIndian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry represent...
- Pharmeasy founders’ new venture All Home raises Rs 200 crore; valuation doublesAll Home, which operates in the interior design and architecture space, partners with brands by investing in them and providing capabilitie...
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chainNiti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...
- India's pharma supply chain remains 65 per cent dependent on China for critical inputs: NITI AayogIndia's pharmaceutical sector, despite being the "pharmacy of the world," faces significant reliance on China for raw materials, with nearl...
- Kunal Shah heads to Meta; New-age IPO playbookHappy Tuesday! Kunal Shah has taken over as WhatsApp's chief, while Meta backs Cred in a major funding deal. This and more in today’s ETtec...
- Plan in the works to let hospitals import med equipment directlyIndia's drug regulator is proposing to allow hospitals to directly import advanced medical equipment like MRI and CT scanners, bypassing cu...
- CBSE to NEET: Centre asks ministries to boost defences against AI threatsFollowing recent cyberattacks, the Indian government is urging all ministries to bolster defenses against AI-driven threats. A nationwide A...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- API prices fall as West Asia tensions ease, boosting Indian pharma sectorPrices for active pharmaceutical ingredients have seen a decline of five to ten percent, thanks to the calming geopolitical climate in West...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26%On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Cancer drug prices raised 50% as NPPA acts on shortage concernsIndia's drug pricing authority has approved a 50% price hike for essential anti-cancer drugs carboplatin and cisplatin. This decision follo...
- Government may lift price cap on cancer drugs making them costlier by up to 50%India's government is taking emergency steps to ensure cancer patients get vital drugs. Cisplatin and carboplatin, crucial chemotherapy age...
Load More
